ASCEND
Pirfenidone in Idiopathic Pulmonary Fibrosis
Patient / Population Intervention / Exposition Comparaison Critère de jugement
In 555 patients with IPF (FVC 50–90% predicted), pirfenidone 2,403 mg/day reduced ≥10% FVC decline or death at 52 weeks compared with placebo.
N
555
Schéma
Multicentre RCT
Critère
≥10% FVC decline or death at 52 weeks
Pertinence
1
Résultat16.5% vs 31.8% (47.9% relative reduction); pooled with CAPACITY, all-cause mortality HR 0.52.
King TE Jr, et al. N Engl J Med. 2014;370(22):2083-2092. 10.1056/NEJMoa1402582
Discussion et critique
Together with CAPACITY, supported FDA approval of pirfenidone.